Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362996 | 0.82 | POLB (0.51) | ALDH1A1MEN1KMT2AALOX15HTT | |
| SCHEMBL1845830 | 0.80 | MEN1 (0.52) | ALDH1A1MEN1KMT2AACHEBCHE | |
| SCHEMBL1847131 | 0.80 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AHPGDTSHR | |
| SCHEMBL356816 | 0.78 | MEN1 (0.51) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1163554 | 0.77 | MEN1 (0.44) | ALDH1A1MEN1KMT2AACHEHTT | |
| SCHEMBL2467964 | 0.76 | TSHR (0.57) | ALDH1A1HTTGAALMNATSHR | |
| SCHEMBL18264884 | 0.75 | PKM (0.46) | ALDH1A1MEN1KMT2APKMALOX15 | |
| SCHEMBL1742531 | 0.75 | PDE4A (0.50) | ALDH1A1ALOX15ACHEGAATSHR | |
| SCHEMBL186800 | 0.75 | MEN1 (0.53) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL17236366 | 0.74 | NPC1 (0.41) | ACHEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | ALDH1A1 1716/4885MEN1 4795/4885KMT2A 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.